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Abstract
Background: Adipose tissue grows by two mechanisms: hyperplasia (cell number increase) and hypertrophy (cell size
increase). Thiazolidinediones are insulin-sensitizing peroxisome proliferator-activated receptor gamma agonists that are
known to affect the morphology of adipose tissue.
Methodology: In this study, adipose cell-size probability distributions were measured in six Zucker fa/fa rats over a period of
24 days, from four weeks of age, using micro-biopsies to obtain subcutaneous (inguinal) fat tissue from the animals. Three
of the rats were gavaged daily with rosiglitazone, a thiazolidinedione, and three served as controls. These longitudinal
probability distributions were analyzed to obtain the rate of increase in cell-size diameter in rosiglitazone-treated animals,
and the hyperplasia induced by treatment quantitatively.
Conclusions: We found that treatment leads to hypertrophy that leads to an approximately linear rate of cell diameter
increase (2 mm/day), and that the hyperplasia evident in treated animals occurs largely within the first eight days of
treatment. The availability of additional lipid storage due to treatment may alleviate lipotoxicity and thereby promote
insulin sensitivity. The hypothesis that a TZD regimen involving repeated treatments of limited duration may suffice for
improvements in insulin sensitivity merits further investigation.
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Introduction
The interplay between adipose tissue state and insulin sensitivity
has been the subject of numerous studies (for a recent review, see
[1,2])). Adipose tissue grows by two mechanisms: hyperplasia (cell
number increase) and hypertrophy (cell size increase). A
dysfunction in the availability of lipid storage, normally provided
by the growth and development of adipocytes, may be a major
contributor to the development of insulin resistance, possibly
associated with low-grade chronic inflammation.
Thiazolidinediones are insulin-sensitizing PPARc agonists that
are known to affect the morphology of adipose tissue. The Zucker
fatty rat is a well-characterized model of obesity. Hallakou et al. [3]
found that pioglitazone (a TZD) treatment of the obese Zucker rat
inducedanincreaseinglucose utilizationinadiposetissue,amarked
increase in weight gain, and stimulated the expression of genes
necessary for lipid metabolism. They also found a large increase in
small adipocyte recruitment in the retroperitoneal fat pad, as well as
a suppression of leptin expression in mature adipocytes. Okuno et al.
[4]foundthattroglitazoneincreasedthenumberofsmalladipocytes
and decreased large adipocytes in obese Zucker rats. de Souza et al.
[5] found that TZD induced adipose tissue remodeling in female
Zucker rats is accompanied by an improvement in insulin
sensitivity, and suggested that this is likely a result of lower
circulating free fatty acid levels. In human, Boden et al. [6] showed
that TZDs had multiple effects on patients with Type 2 diabetes,
including an increase in small adipocytes in subcutaneous adipose
tissue; see also Smith et al. [7] and McLaughlin et al. [8].
In preliminary experiments (D. Hunt et al., unpublished data),
we measured adipose cell-size probability distributions in control
and rosiglitazone-treated Zucker fatty rats. These cell-size
distributions allow detailed investigation of mechanisms of growth
and development of adipose tissue. We observed dynamic changes
in cell sizes, appearing to show an acute recruitment of cells to the
adipose cell type in treated animals, but the control animals
showed dynamic adipose cell-size distributions as well, rendering it
difficult to quantify the extent of thiazolidinedione involvement in
the dynamic changes. We also observed considerable between–
animal variability in these preliminary experiments.
To address TZD effects on the morphology of fat tissue
concretely, we obtained cell-size distributions of the inguinal fat
pads in six male Zucker (fa/fa) fatty rats by micro-biopsies
(Materials and Methods) over a period of 24 days respectively,
starting at four weeks of age. This animal model has fat depots that
are large enough to allow repeated micro-biopsies to avoid
between-animal variability. We developed a Bayesian framework
to quantify both the hyperplasia and hypertrophy induced by
TZD treatment from these data. Applying the framework, we
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hyperplasia within eight days of treatment, and that the treatment
leads to an increase in hypertrophy relative to control in
intermediate-sized adipocytes.
Results
Adipose Cell-Size Distributions
Representative mean adipose cell-size distributions (see Materials
and Methods) comparing treated and control rats on days 0, 16 and
24 are shown in Figs. 1–3. These distributions show dynamics in both
control and treated animals. However, a comparison of the changes
in the adipose cell-size probability distributions between measured
time-points (Figs. 5 and 6) shows a pattern of size increase in treated
rats that is distinct from changes in control animals. A heat-map
allows a clear visualization of the complete data set showing a linear
progression of cell size increase in treated animals (Fig. 4).
Log-Likelihood of Rate of Cell-Size Increase
We evaluated the likelihood of a large range (0 to 7.9 mm/day)
of rates of adipose cell diameter increase, shown in Fig. 7. The
expectation value of the rate of adipose cell diameter increase was
2.02 mm=day (st. dev. 0:58 mm=day) for treated animals and 0:44
mm=day (st. dev. 0.23 mm=day) for control.
Adipose Cell Recruitment
We evaluated the maximum-likelihood value for the total adipose
cell number for all following days of treatment, as a ratio relative to
the initial total adipose cell number. The treated animals showed
larger relative adipose cell numbers at all time points, as shown in
Fig. 8. The treated animals show about 20% more cells by day 8
with a much slower increase at later time points.
Size-Dependence of Rate of Adipose Cell-Size Increase
We investigated possible size dependence of the rate of adipose
cell-size increase by performing our analysis on a moving interval
of a hundred cell-size bins. The results are shown in Figs. 9 and 10,
suggesting that the change in the rate of adipose cell-size increase
connected with treatment primarily affects intermediate (70–120
mm diameter) adipocytes. The slope of the arrow depicted in Fig. 4
(approximately 4 mm/day) is consistent with the rate of adipose cell
diameter increase at intermediate sizes evident in Fig. 10.
Figure 1. Adipose cell-size probability distributions for treated vs. control animals for day 0.
doi:10.1371/journal.pone.0008196.g001
Figure 2. Adipose cell-size probability distributions for treated vs. control animals for day 16.
doi:10.1371/journal.pone.0008196.g002
TZD Effects on Adipocytes
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PPARc [9] is a nuclear receptor whose agonists include fatty
acids and thiazolidinediones. The activation of PPARc potentially
affects a large number of physiological processes, including
adipocyte differentiation, with actual activity determined in
combination with various co-activators. TZDs improve peripheral
insulin sensitivity. Their impact on adipocytes has also been
studied [3,2].
Our results show that TZD treatment leads to more adipocytes,
and greater energy uptake by intermediate-sized adipocytes, in the
inguinal fat pad of the Zucker fatty rat. We have quantitatively
shown that treatment-induced hyperplasia is more or less complete
within the first eight days of treatment, with subsequent
hyperplasia at a much slower rate. We have also found that an
increase in hypertrophy induced by treatment occurs mainly in
intermediate-sized adipocytes. This hypertrophy may be related to
the greater glucose utilization induced by TZD treatment [3], that
in turn may be linked to increased insulin sensitivity in adipocytes
[2]. A similar size range for hypertrophy was found in [10],
suggesting that the size range for hypertrophy is independent of
the stimulus for generating larger adipocytes. On the other hand,
the availability of additional adipocytes in a size range capable of
additional energy storage due to treatment may itself alleviate
hyperglycemia by enabling liponeogenesis.
In data obtained in our laboratory (D. Hunt et al., unpublished)
under a protocol in which the rats were killed at days 2, 6, 10 and
14, the insulin sensitizing effects of TZDs appear by day 2 of
treatment but there is an decrease in plasma glucose area-under-
the-curve (AUC) (Fig. 11) between day 6 and day 10 without a
concurrent additional drop in insulin AUC (Fig. 12). This suggests
that the availability of additional energy storage in the form of
adipocyte recruitment by day 8 (Fig 8) leads to glucose removal
Figure 3. Adipose cell-size probability distributions for treated vs. control animals for day 24.
doi:10.1371/journal.pone.0008196.g003
Figure 4. Heat-map of adipose cell-size distributions, showing
dynamics in both control and treated animals, with the
propagation of a rosiglitazone-induced pulse of adipocytes
in treated animals.
doi:10.1371/journal.pone.0008196.g004
Figure 5. Differences of adipose cell-size probability distribu-
tions at successive time points for control animals. The curves
s h o wt h ed i f f e r e n c eb e t w e e ns u c c eeding day adipose cell-size
probability distributions at each cell-size bin s–-for example, the curve
labeled (day 12 – day 8) shows Prob(day 12, s) – Prob(day 8, s).
doi:10.1371/journal.pone.0008196.g005
TZD Effects on Adipocytes
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tissue. This may support the hypotheses of de Souza et al. [5].
The hypothesis that a TZD regimen involving repeated
treatments of limited duration may suffice for improvements in
insulin sensitivity merits further investigation.
Materials and Methods
Surgical Biopsies
All procedures were carried out in accordance with NIH
guidelines for rodent surgery and recovery. Six rats were
subjected to the biopsies. Rats were anesthetized with isoflurane.
The hair in the inguinal area was clipped and the skin cleaned
three times with betadine surgical scrub, followed with an alcohol
wipe. For adipogenesis studies in individual animals using surgical
biopsies, the sampling procedure involves a small incision (*
0.1 cm) in the skin just above the inguinal fat depot that lies
immediately thereunder, dissection of a 15–20-mg sample of
adipose tissue, and closing the incision with stainless steel clips.
Clips were removed between 10–17 days. Significant pain and
distress were not evident, but animals were closely observed for
2/3 h for potential problems. The inguinal fat depot surrounds
the back side of the peritoneum, extending all the way from one
hip to the other. Representative samples can be taken all across
the fat depot and thus the incisions can be dispersed without
giving up the required reproducibility. The biopsies were done on
days 0, 8, 12, 16, 20 and 24; on each day for each rat, duplicate
biopsies were obtained, one each from similar sites on each side
of the midline.
Treatment
The rats were randomized into two equal groups: three animals
treated with vehicle (water) and three treated with rosiglitazone.
The rosiglitazone group was dosed (3 mg/kg) daily via oral gavage
for the duration of the experiment (24 days).
Measurement of Adipose Cell-Size
Adipose cell-size distribution was assessed using a Beckman
Coulter Multisizer III as previously described [11]. Briefly, 15–
20 mg of fat were immediately fixed in osmium tetroxide [12] and
incubated in a water bath at 370C for 48 h. Adipose cell-size was
then determined by a Beckman Coulter Multisizer III with a 400
mm aperture. The range of cell-sizes that can effectively be
measured using this aperture is 20–240 mm. The instrument was
set to count 6,000 particles, and the fixed-cell suspension was
Figure 6. Differences of adipose cell-size probability distribu-
tions at successive time points for treated animals. The treated
animal differences show a hump of cells moving to larger sizes; this
hump is not evident in the contol animals.
doi:10.1371/journal.pone.0008196.g006
Figure 7. Log-likelihood values for rates of adipose cell
diameter increase for control and treated animals. The log-
likelihood values for control animals are highest close to 0.44 mm/day
whereas the log-likelihood values are highest around 2 mm/day for
treated animals.
doi:10.1371/journal.pone.0008196.g007
Figure 9. Values and standard deviations of cell-size depen-
dence of rates of cell diameter increase for control animals.
doi:10.1371/journal.pone.0008196.g009
Figure 8. Relative cell number (Total cell number/Total cell
number at day 0) as a function of time for control and treated
animals.
doi:10.1371/journal.pone.0008196.g008
TZD Effects on Adipocytes
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pulse sizes, the data were expressed as particle diameters and
displayed as histograms of counts against diameter using linear
bins and a linear scale for the cell diameter. Cell-size distribution
was measured four times from each biopsy, divided into two
separate suspensions that were each counted twice.
Bayesian Analysis of Data
The aim of our analysis was to analyze longitudinal adipose cell-
size distributions to quantitatively characterize hypertrophy and
hyperplasia of adipose tissue in Zucker fatty rats induced by
rosiglitazone. We introduced a set of models in which cell diameter
grew linearly at differing rates, ranging from 0 to 7.9 mm/day, in
increments of 0.1 mm/day. For a given model of rate v mm/day,
we expected that cells at diameter s mm will have increased in size
to szvd mm after d days. Given that the data consists of
probability distributions of cell-sizes but not absolute cell numbers,
we also had to infer a change in the absolute cell number, since we
were comparing absolute cell numbers in such a comparison of
cell-size change as a function of d days. Thus, we introduced a
relative cell number parameter Nd for each day after day 0 of the
experiment, with N0~1. We took the log of the probability of the
data, given the model, to be the sum over bin sizes, s, and pairs of
successive time points, (d,dzD),o f
{ Ndp(d,s){NdzDp(dzD,szvD) ðÞ
2
.
s2; ð1Þ
here, p(d,s) is the adipose cell-size probability distribution at
diameter s on day d.
We marginalized over s and Nd using a parallel tempered
Monte Carlo procedure given by Gregory [13], with uninforma-
tive priors for all variables. The initial value of Nd was taken to be
1 for all days, and the initial value of s was taken to be 0.05, the
estimated measurement uncertainty in the data. The Markov
Chain Monte Carlo carried out equilibration for 3000 steps (with a
mean fractional parameter step size of 0.05) and then marginalized
over the next 300 steps (with a mean fractional parameter step size
of 0.01). During the equilibration time, the parallel tempering
procedure switched the ten evenly spaced temperatures with a
probability of 0.05, corresponding to about once every twenty
steps. After equilibration, the parallel tempering steps were all
started from the same initial value, the maximum likelihood value
found during the equilibration phase of the Monte Carlo
procedure, and did not undergo any further switching between
Figure 10. Values and standard deviations of cell-size depen-
dence of rates of cell diameter increase for treated animals.
Treated animals show greater rates of cell-diameter increase at
intermediate sizes.
doi:10.1371/journal.pone.0008196.g010
Figure 11. Area-under-the-curve for glucose for Zucker fatty
rats, treated with rosiglitazone and control, under an oral
glucose tolerance test. The data shown is the mean from three
independent experiments with three rats each in control and treated
groups. The SEM for the data is 10%.
doi:10.1371/journal.pone.0008196.g011
Figure 12. Area-under-the-curve for insulin for Zucker fatty
rats, treated with rosiglitazone and control, under an oral
glucose tolerance test. The data shown is the mean from three
independent experiments with three rats each in control and treated
groups. The SEM for the data is 10%.
doi:10.1371/journal.pone.0008196.g012
TZD Effects on Adipocytes
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interpretation of parallel tempering was valid.
To determine the size-dependence of the rate of cell-diameter
increase, we carried out the entire analysis as described above on
moving windows of a hundred cell-size bins (corresponding to a
window of 60 mm). The probability-weighted mean velocity for the
moving cell-size windows is plotted in Figs. 9 and 10, with the
probability-weighted standard deviations as the uncertainty bars.
All analysis was performed in XLispStat [14].
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